Markets

The Fundamental Case for and Against Amneal Pharmaceuticals, Inc. (AMRX)

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) is an interesting stock at present. Now trading with a market value of 1.44B, the company has a mix of catalysts and obstacles that spring from the nature of its operations. As the day-to-day narrative ebbs and flows for this company, it is more important than ever to step back and get a bird’s eye view of the fundamental reality under the surface of this story.

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For AMRX, the company currently has 181.78 million of cash on the books, which is offset by 17.85 million in current liabilities. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has 1.35 billion in total assets, balanced by 1.16 billion in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

Amneal Pharmaceuticals, Inc. (AMRX) saw 34.84 million in free cash flow last quarter, representing a quarterly net change in cash of 24.12 million. Perhaps most importantly where cash movements are concerned, the company saw about 37.41 million in net operating cash flow.

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 182.91 million in total revenues. That represents a quarterly year/year change in revenues of -0.08 in sequential terms, the AMRX saw sales decline by -0.11.



But what about the bottom line? After all, that’s what really matters in the end. Amneal Pharmaceuticals, Inc. (AMRX) is intriguing when broken down to its core data. The cost of selling goods last quarter was 122.6 million, yielding a gross basic income of 60.32 million. For shareholders, given the total diluted outstanding shares of 72.1 million, this means overall earnings per share of -4.18. Note, this compares with a consensus analyst forecast of 0.26 in earnings per share for its next fiscal quarterly report.

Is Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Valuation Attractive

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about 1.46 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 12.53. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Amneal Pharmaceuticals, Inc..

Previous ArticleNext Article

Related Post

For Transocean Ltd. (RIG), It May Be As Good A Mom... Transocean Ltd. (NYSE:RIG) trade is getting exciting but lets take a deeper look whether it is as good a moment. Now trading with a market value of 4....
Checking Out the Fundamental Data for Lennar Corpo... Lennar Corporation (NYSE:LEN) is one of the active stocks and its unusual movement is raising eyebrows among traders. Now trading with a market value ...
Looking at the Big Picture for Molina Healthcare, ... Molina Healthcare, Inc. (NYSE:MOH) trade is getting exciting but lets take a deeper look whether it is as good a moment. Now trading with a market val...
BRF S.A. (BRFS): Interesting Series Of Development... BRF S.A. (NYSE:BRFS) has recently been identified as an interesting stock but more in-depth monitoring is needed for a trade decision. Now trading wit...
Does Netflix, Inc. (NFLX) Present Much Upside ? Netflix, Inc. (NASDAQ:NFLX) has recently been identified as an interesting stock but more in-depth monitoring is needed for a trade decision. Now trad...